Loading companies…

Genetic Signatures Ltd ASX:GSS

0 opened or increased0 held0 reduced or exitedlatest position by manager, past 12 months90 days: 0 increased, 0 reduced. 1 managers in total.

Position history by manager 1 managersSelect a point to see the comment

Opened or increasedHeldReduced or exited Start or end of the position not reported

202420252026

31 Jul 2023 to today

Commentary Showing 2 of 7

DateManagerActionSummary

31 Jul 2025Pengana Capital GroupHeldPengana Capital Group continues to hold Genetic Signatures Ltd because the company remains optimistic about signing new customers for its FDA-approved enteric gut bug molecular test and expects new customer signings over coming months. Pengana Capital Group notes the market has been disappointed by slow progress in adding customers and revenue since the FDA approval approximately one year ago.

Medical DevicesMonthly Report, price recorded $0.33

The source document link is a Pro feature

30 Apr 2025Pengana Capital GroupHeldThe fund continues to hold Genetic Signatures, noting shares fell 19% after releasing its quarterly report with investors disappointed that no new customers had been signed for its new enteric gut bug PCR test. The manager notes the company highlighted several customers in the late stages of the procurement process, and notes the highly consolidated U.S. laboratory testing market means contract wins may potentially be significant.

Monthly Report, price recorded $0.41

The source document link is a Pro feature

5 more comments on GSSPro shows every comment, with a link to each source document.

Upgrade to Pro

First mention by manager

Price recorded at each manager's first comment

Price at first mentionThe share price recorded when each of 1 managers first commented on GSS.

View Pro

About Genetic Signatures Ltd

Healthcare, Life Sciences Tools and Services

Genetic Signatures (ASX:GSS), a molecular diagnostics company, has disappointed investors with slow US progress. In July 2025, Pengana reported Genetic Signatures fell 10% after quarterly earnings, noting the market had been disappointed by slow progress in winning US customers. In April 2025, Pengana noted a 19% fall after no new US customers were announced. Earlier, Pengana reported gains after new CEO Allison Rossiter, formerly head of Roche Australia, met investors, and after strong sales of its influenza test. Genetic Signatures operates in the Healthcare sector within the Life Sciences Tools and Services industry, and Thesis Tracker has captured 7 comments from 1 fund manager, Pengana Capital Group. Founded in 2001 and headquartered in Sydney, Genetic Signatures develops EasyScreen molecular diagnostic tests for infectious diseases, including gastrointestinal, respiratory and sexually transmitted infections, using its proprietary 3base technology, and is seeking to expand in the United States after FDA clearance of its enteric panel.

Market cap: $18m
Price to earnings: Loss-making
Return on equity: -32.6%
Dividend yield: 0.0%
Price to book: 0.53x
Net margin: -72.5%
52-week range: $0.05 to $0.43

Company figures as of 15 Oct 2026. For information only.

Questions

Who is investing in Genetic Signatures Ltd (ASX:GSS)?

Fund managers including Pengana Capital Group have invested in Genetic Signatures Ltd (ASX:GSS).

What opportunities or catalysts do fund managers highlight for Genetic Signatures Ltd?

Pengana highlights strong influenza test sales in Australia, FDA clearance enabling US expansion and a new CEO with major diagnostics industry experience.

What are the key risks to the Genetic Signatures Ltd investment thesis, according to fund managers?

Pengana notes slow progress in winning US customers, with quarterly reports showing no new customers, leading to repeated share price falls.

What does Genetic Signatures Ltd (ASX:GSS) do?

Genetic Signatures Ltd. is an Australian-headquartered research company specializing in the identification and commercialization of genetic signatures for diagnosing infectious diseases. Founded in 2001, the company develops and sells diagnostic products for gastrointestinal, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical diseases. Genetic Signatures serves global markets across the Asia Pacific, EMEA, and Americas regions. The firm focuses on diagnostic and research marketplace solutions, utilizing proprietary technology to detect pathogens and improve clinical outcomes.

General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.

11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.

Disclaimer Terms of Use Privacy Complaints Contact

Loading…